X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3249) 3249
Publication (360) 360
Book Review (31) 31
Newsletter (29) 29
Magazine Article (27) 27
Book Chapter (10) 10
Conference Proceeding (5) 5
Newspaper Article (3) 3
Trade Publication Article (2) 2
Data Set (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (3042) 3042
male (2900) 2900
prostate-specific antigen - blood (1773) 1773
prostate cancer (1758) 1758
index medicus (1547) 1547
aged (1521) 1521
prostatic neoplasms - drug therapy (1364) 1364
androgen antagonists - therapeutic use (1318) 1318
middle aged (1305) 1305
prostatic neoplasms - pathology (1143) 1143
oncology (1127) 1127
prostate-specific antigen (1039) 1039
urology & nephrology (987) 987
cancer (862) 862
prostatic neoplasms - blood (857) 857
aged, 80 and over (769) 769
treatment outcome (665) 665
care and treatment (600) 600
prostate (538) 538
prostatic neoplasms - therapy (502) 502
prostatic neoplasms - radiotherapy (490) 490
antineoplastic agents, hormonal - therapeutic use (481) 481
radiotherapy (445) 445
prostatic neoplasms - mortality (439) 439
radical prostatectomy (439) 439
carcinoma (430) 430
men (399) 399
neoplasm staging (394) 394
prostatic neoplasms - metabolism (391) 391
androgens (386) 386
prognosis (386) 386
prostatectomy (377) 377
prostate-specific antigen - metabolism (376) 376
disease progression (356) 356
disease-free survival (356) 356
follow-up studies (350) 350
therapy (350) 350
animals (343) 343
retrospective studies (336) 336
cell line, tumor (329) 329
prostatic neoplasms - surgery (324) 324
research (322) 322
time factors (322) 322
survival (319) 319
metastasis (304) 304
urology (304) 304
radiology, nuclear medicine & medical imaging (294) 294
analysis (284) 284
androgen antagonists - administration & dosage (281) 281
antigens (281) 281
antigen (275) 275
androgen receptor (274) 274
receptors, androgen - metabolism (272) 272
risk factors (270) 270
combined modality therapy (269) 269
prostatic neoplasms - diagnosis (268) 268
biomarkers, tumor - blood (264) 264
expression (264) 264
health aspects (262) 262
hematology, oncology and palliative medicine (258) 258
adult (242) 242
radiation-therapy (241) 241
article (237) 237
orchiectomy (233) 233
adenocarcinoma - drug therapy (227) 227
antineoplastic agents - therapeutic use (224) 224
progression (224) 224
chemotherapy (222) 222
prostatic neoplasms (219) 219
prospective studies (214) 214
endocrinology & metabolism (211) 211
testosterone (211) 211
prostate-specific antigen - genetics (208) 208
survival rate (205) 205
biochemistry & molecular biology (192) 192
prostatic neoplasms - genetics (192) 192
androgen antagonists - adverse effects (189) 189
patients (188) 188
receptors, androgen - genetics (187) 187
survival analysis (187) 187
mice (186) 186
castration (184) 184
docetaxel (184) 184
quality of life (183) 183
testosterone - blood (182) 182
androgen deprivation therapy (179) 179
risk (171) 171
radiology (170) 170
neoplasm grading (167) 167
antineoplastic combined chemotherapy protocols - therapeutic use (166) 166
cells (166) 166
neoplasm metastasis (166) 166
bone neoplasms - secondary (164) 164
prostate-specific antigen - analysis (164) 164
prostatic neoplasms, castration-resistant - drug therapy (163) 163
oncology, experimental (162) 162
prostate - pathology (162) 162
psa (161) 161
trial (161) 161
androgen antagonists - pharmacology (159) 159
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3119) 3119
Japanese (51) 51
French (44) 44
German (35) 35
Spanish (21) 21
Russian (16) 16
Chinese (10) 10
Italian (6) 6
Hungarian (3) 3
Dutch (2) 2
Serbian (2) 2
Bulgarian (1) 1
Czech (1) 1
Finnish (1) 1
Korean (1) 1
Portuguese (1) 1
Slovak (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal of Medicinal Chemistry, ISSN 0022-2623, 03/2016, Volume 59, Issue 5, pp. 1761 - 1775
Journal Article
Journal Article
Journal Article
Journal Article
Biochemical and Biophysical Research Communications, ISSN 0006-291X, 11/2015, Volume 467, Issue 2, pp. 310 - 315
Recently, lysine-specific demethylase 1 (LSD1) was identified as the first histone demethylase. LSD1 interacted with androgen receptor (AR) and promoted... 
Epithelial–mesenchymal transition | Androgen deprivation therapy | Pargyline | Castration resistant prostate cancer | LSD1 | Epithelial-mesenchymal transition | INVASION | BIOPHYSICS | DEMETHYLATION | BIOCHEMISTRY & MOLECULAR BIOLOGY | ANDROGEN-RECEPTOR | Antihypertensive Agents - pharmacology | Histone Demethylases - antagonists & inhibitors | Cadherins - agonists | Cadherins - metabolism | Vimentin - metabolism | Humans | Receptors, Androgen - metabolism | Gene Expression Regulation, Neoplastic | Epithelial-Mesenchymal Transition - drug effects | Male | Epithelial-Mesenchymal Transition - genetics | Histone Demethylases - genetics | Prostatic Neoplasms, Castration-Resistant - genetics | Prostatic Neoplasms, Castration-Resistant - pathology | Vimentin - genetics | Antineoplastic Agents - pharmacology | Prostate-Specific Antigen - metabolism | Cadherins - genetics | Prostate-Specific Antigen - genetics | Signal Transduction | Enzyme Inhibitors - pharmacology | Drug Repositioning | Prostatic Neoplasms, Castration-Resistant - drug therapy | Mice, SCID | Prostatic Neoplasms, Castration-Resistant - metabolism | Disease Progression | Xenograft Model Antitumor Assays | Histone Demethylases - metabolism | Animals | Receptors, Androgen - genetics | Cell Line, Tumor | Pargyline - pharmacology | Mice, Inbred NOD | Prostate-Specific Antigen - antagonists & inhibitors | Cadherins - antagonists & inhibitors | Mice | Vimentin - antagonists & inhibitors | Cell Movement | Development and progression | Prostate cancer | Intermediate filament proteins | Stem cells
Journal Article
Journal Article
JOURNAL OF HEMATOLOGY & ONCOLOGY, ISSN 1756-8722, 04/2017, Volume 10, Issue 1, pp. 95 - 14
Treatment of cancer patients involves a multidisciplinary approach including surgery, radiotherapy, and chemotherapy. Traditionally, patients with metastatic... 
BLADDER-CANCER | BACILLUS-CALMETTE-GUERIN | Durvalumab | Interleukin | Ipilimumab | PROSTATE-SPECIFIC ANTIGEN | Bladder | Kidney | RENAL-CELL CARCINOMA | Pembrolizumab | Immunotherapy | PD-L1 | CTLA-4 | Sipuleucel-T | HIGH-DOSE INTERLEUKIN-2 | HEMATOLOGY | CLINICAL ACTIVITY | Checkpoint inhibitor | BCG | FREQUENT PD-L1 EXPRESSION | Genitourinary malignancy | PROSTVAC | ONCOLOGY | PHASE-I TRIAL | Nivolumab | ACTIVATED KILLER-CELLS | PD-1 | Prostate | Cancer | Atezolizumab | Adaptive Immunity | Humans | Interferon-alpha - therapeutic use | Interleukin-2 - therapeutic use | Neoplasm Proteins - immunology | Antibodies, Monoclonal - therapeutic use | Neoplasm Proteins - antagonists & inhibitors | Programmed Cell Death 1 Receptor - antagonists & inhibitors | Clinical Trials as Topic | CTLA-4 Antigen - immunology | Immunity, Innate | B7-H1 Antigen - immunology | Cancer Vaccines - therapeutic use | B7-H1 Antigen - antagonists & inhibitors | Multicenter Studies as Topic | Antineoplastic Agents, Immunological - therapeutic use | Urogenital Neoplasms - therapy | Biomarkers | Programmed Cell Death 1 Receptor - immunology | CTLA-4 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - immunology | Antigens | Cytokines | Palliation | Melanoma | Clinical trials | Cytotoxicity | Metastasis | Radiation therapy | Cancer therapies | Metastases | Side effects | Chemotherapy | Lymphocytes | Medical prognosis | Surgery | Ligands | Interferon | Prostate cancer | Cytotoxic agents | Immune system | Tumors
Journal Article
Journal Article